

B6

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/75093 A1

(51) International Patent Classification⁷: **C12N 15/00**,
15/12, C07K 14/435

CA 94087 (US). **REN, Feiyang** [US/US]; 7703 Oak Meadow Court, Cupertino, CA 95014 (US). **ZHANG, Jie** [CN/US]; 4930 Poplar Terrace, Campbell, CA 95008 (US). **WANG, Jian-Rue** [CN/US]; 744 Stendhal Lane, Cupertino, CA 95014 (US). **XU, Chongjun** [US/US]; 4918 Manitoba Drive, San Jose, CA 95130 (US). **YANG, Yonghong** [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). **ZAHO, Qing, A.** [CN/US]; 1556 Kooser Road, San Jose, CA 95118 (US). **CHEN, Rui-hong** [US/US]; 1031 Flying Fish Street, Foster City, CA 94404 (US). **WANG, Dunrui** [CN/US]; 932 La Palma, Milpitas, CA 95035 (US). **GOODRICH, Ryle, W.** [US/US]; 4896 Sandy Lane, San Jose, CA 95124 (US). **LIU, Chenghua** [CN/US]; 1125 Ranchero Way, Apt. #14, San Jose, CA 95117 (US). **DRMANAC, Radoje, T.** [YU/US]; 850 East Greenwich Place, Palo Alto, CA 94303 (US).

(21) International Application Number: PCT/US01/10484

(22) International Filing Date: 30 March 2001 (30.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/540,217	31 March 2000 (31.03.2000)	US
09/649,167	23 August 2000 (23.08.2000)	US
09/668,680	22 September 2000 (22.09.2000)	US
09/695,618	23 October 2000 (23.10.2000)	US
09/728,711	30 November 2000 (30.11.2000)	US
Not furnished	14 March 2001 (14.03.2001)	US

(74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	09/540,217 (CIP)
Filed on	31 March 2000 (31.03.2000)
US	09/649,167 (CIP)
Filed on	23 August 2000 (23.08.2000)
US	09/668,680 (CIP)
Filed on	22 September 2000 (22.09.2000)
US	09/695,618 (CIP)
Filed on	23 October 2000 (23.10.2000)
US	09/728,711 (CIP)
Filed on	30 November 2000 (30.11.2000)
US	Not furnished (CIP)
Filed on	14 March 2001 (14.03.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/75093 A1

(54) Title: NOVEL NUCLEIC ACIDS AND POLYPEPTIDES

(57) Abstract: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-43, or 87-129, a mature protein coding portion of SEQ ID NO: 1-43, or 87-129, an active domain coding portion of SEQ ID NO: 1-43, or 87-129, and 5 complementary sequences thereof.
 2. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide hybridizes to the polynucleotide of claim 1 under stringent hybridization conditions.
- 10
3. An isolated polynucleotide encoding a polypeptide with biological activity, wherein said polynucleotide has greater than about 90% sequence identity with the polynucleotide of claim 1.
 4. The polynucleotide of claim 1 wherein said polynucleotide is DNA.
- 15
5. An isolated polynucleotide of claim 1 wherein said polynucleotide comprises the complementary sequences.
 6. A vector comprising the polynucleotide of claim 1.
- 20
7. An expression vector comprising the polynucleotide of claim 1.
 8. A host cell genetically engineered to comprise the polynucleotide of claim 1.
- 25
9. A host cell genetically engineered to comprise the polynucleotide of claim 1 operatively associated with a regulatory sequence that modulates expression of the polynucleotide in the host cell.
 10. An isolated polypeptide, wherein the polypeptide is selected from the group consisting of:
 - (a) a polypeptide encoded by any one of the polynucleotides of claim 1; and
 - (b) a polypeptide encoded by a polynucleotide hybridizing under stringent conditions with any one of SEQ ID NO: 1-43, or 87-129.
- 30
11. A composition comprising the polypeptide of claim 10 and a carrier.

12. An antibody directed against the polypeptide of claim 10.

13. A method for detecting the polynucleotide of claim 1 in a sample, comprising:

- a) contacting the sample with a compound that binds to and forms a complex with the polynucleotide of claim 1 for a period sufficient to form the complex; and
- b) detecting the complex, so that if a complex is detected, the polynucleotide of claim 1 is detected.

14. A method for detecting the polynucleotide of claim 1 in a sample, comprising:

- 10 a) contacting the sample under stringent hybridization conditions with nucleic acid primers that anneal to the polynucleotide of claim 1 under such conditions;
- b) amplifying a product comprising at least a portion of the polynucleotide of claim 1; and
- c) detecting said product and thereby the polynucleotide of claim 1 in the

15 sample.

15. The method of claim 14, wherein the polynucleotide is an RNA molecule and the method further comprises reverse transcribing an annealed RNA molecule into a cDNA polynucleotide.

20 16. A method for detecting the polypeptide of claim 10 in a sample, comprising:

- a) contacting the sample with a compound that binds to and forms a complex with the polypeptide under conditions and for a period sufficient to form the complex; and
- b) detecting formation of the complex, so that if a complex formation is detected, the polypeptide of claim 10 is detected.

25

17. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:

- a) contacting the compound with the polypeptide of claim 10 under conditions sufficient to form a polypeptide/compound complex; and
- 30 b) detecting the complex, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

18. A method for identifying a compound that binds to the polypeptide of claim 10, comprising:

a) contacting the compound with the polypeptide of claim 10, in a cell, under conditions sufficient to form a polypeptide/compound complex, wherein the complex drives expression of a reporter gene sequence in the cell; and

5 b) detecting the complex by detecting reporter gene sequence expression, so that if the polypeptide/compound complex is detected, a compound that binds to the polypeptide of claim 10 is identified.

19. A method of producing the polypeptide of claim 10, comprising,

10 a) culturing a host cell comprising a polynucleotide sequence selected from SEQ ID NO: 1-43, or 87-129, a mature protein coding portion of SEQ ID NO: 1-43, or 87-129, an active domain coding portion of SEQ ID NO: 1-43, or 87-129, complementary sequences thereof and a polynucleotide sequence hybridizing under stringent conditions to SEQ ID NO: 1-43, or 87-129, under conditions sufficient to express the polypeptide in said cell; and

15 b) isolating the polypeptide from the cell culture or cells of step (a).

20. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of any one of the polypeptides SEQ ID NO: 44-86, or 130-172, the mature protein portion thereof, or the active domain thereof.

20 21. The polypeptide of claim 20 wherein the polypeptide is provided on a polypeptide array.

22. A collection of polynucleotides, wherein the collection comprising the sequence information of at least one of SEQ ID NO: 1-43, or 87-129.

25 23. The collection of claim 22, wherein the collection is provided on a nucleic acid array.

24. The collection of claim 23, wherein the array detects full-matches to any one of the polynucleotides in the collection.


30 25. The collection of claim 23, wherein the array detects mismatches to any one of the polynucleotides in the collection.

35 26. The collection of claim 22, wherein the collection is provided in a computer-readable format.

27. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.

5

28. A method of treatment comprising administering to a mammalian subject in need thereof a therapeutic amount of a composition comprising an antibody that specifically binds to a polypeptide of claim 10 or 20 and a pharmaceutically acceptable carrier.




WO 01/75093


Leu Phe Phe Cys Leu Pro Met Ala Ile Met Ser Val Leu Tyr Leu Leu			
260	265	270	
att ggg ctg cga ctg cgg cgg gag agg ctg ctg ctc atg cag gag gcc		864	
Ile Gly Leu Arg Leu Arg Arg Glu Arg Leu Leu Leu Met Gln Glu Ala			
275	280	285	
aag ggc agg ggc tct gca gca gcc agg tcc aga tac acc tgc agg ctc		912	
Lys Gly Arg Gly Ser Ala Ala Arg Ser Arg Tyr Thr Cys Arg Leu			
290	295	300	
cag cag cac gat cgg ggc cgg aga caa gtg acc aag atg ctg ttt gtc		960	
Gln Gln His Asp Arg Gly Arg Arg Gln Val Thr Lys Met Leu Phe Val			
305	310	315	320
ctg gtc gtg gtg ttt ggc atc tgc tgg gcc ccg ttc cac gcc gac cgc		1008	
Leu Val Val Val Phe Gly Ile Cys Trp Ala Pro Phe His Ala Asp Arg			
325	330	335	
gtc atg tgg agc gtc gtg tca cag tgg aca gat ggc ctg cac ctg gcc		1056	
Val Met Trp Ser Val Val Ser Gln Trp Thr Asp Gly Leu His Leu Ala			
340	345	350	
ttc cag cac gtg cac gtc atc tcc ggc atc ttc ttc tac ctg ggc tgg		1104	
Phe Gln His Val His Val Ile Ser Gly Ile Phe Phe Tyr Leu Gly Ser			
355	360	365	
gcg gcc aac ccc gtg ctc tat agc ctc atg tcc agc cgc ttc cga gag		1152	
Ala Ala Asn Pro Val Leu Tyr Ser Leu Met Ser Ser Arg Phe Arg Glu			
370	375	380	
acc ttc cag gag gcc ctg tgc ctc ggg gcc tgc tgc cat cgc ctc aga		1200	
Thr Phe Gln Glu Ala Leu Cys Leu Gly Ala Cys Cys His Arg Leu Arg			
385	390	395	400
ccc cgc cac agc tcc cac agc ctc agc agg atg acc aca ggc agc acc		1248	
Pro Arg His Ser Ser His Ser Leu Ser Arg Met Thr Thr Gly Ser Thr			
405	410	415	
ctg tgt gat gtg ggc tcc ctg ggc agc tgg gtc cac ccc ctg gct ggg		1296	
Leu Cys Asp Val Gly Ser Leu Gly Ser Trp Val His Pro Leu Ala Gly			
420	425	430	
aac gat ggc cca gag gcg cag caa gag acc gat cca tcc tgagtggagc		1345	
Asn Asp Gly Pro Glu Ala Gln Gln Glu Thr Asp Pro Ser			
435	440	445	
cttaaagtgg cttcacctgg aggggccaga gggcacctg gagctgggaa gacacatctg		1405	
ccttcctctg cagggatgcc ttcacgtact gtcccttagtt cagcctagaa attctgacca		1465	
gcacacctgt ttccctcaga gggaaacagc aggaggaggg atccctgact gctgaggact		1525	
cacactgacc		1535	

<210> 11
<211> 1539
<212> DNA
<213> Homo sapiens

<220>




<221> CDS		
<222> (130) .. (1536)		
<400> 11		60
gcacgaggtg gaggacgcgg ctgttcaag tccctggc tc tgatccaggc cacagattcc		
aggattctac aggcaggaaa catcttagaa atcagggttg ggcaggcagg agccaggaga		120
gtagctaca atg act tca cca gta ctg gtg gac ata cga gaa gag gtg		168
Met Thr Ser Pro Val Leu Val Asp Ile Arg Glu Glu Val		
1 5 10		
acc tgc cct atc tgc ctg gag ctc cta aca gaa ccc ctg agc ata gac		216
Thr Cys Pro Ile Cys Leu Glu Leu Leu Thr Glu Pro Leu Ser Ile Asp		
15 20 25		
tgt ggc cac agc ttc tgc caa gcc tgc atc aca cca aat ggc agg gaa		264
Cys Gly His Ser Phe Cys Gln Ala Cys Ile Thr Pro Asn Gly Arg Glu		
30 35 40 45		
tca gtg att ggt caa gaa ggg gaa aga agc tgc cct gtg tgc cag acc		312
Ser Val Ile Gly Gln Glu Gly Glu Arg Ser Cys Pro Val Cys Gln Thr		
50 55 60		
agc tac cag cca ggg aac ctg cgg cct aat cgg cat ctg gcc aac ata		360
Ser Tyr Gln Pro Gly Asn Leu Arg Pro Asn Arg His Leu Ala Asn Ile		
65 70 75		
gtg agg cgg ctc aga gag gta gtg ttg ggc cct ggg aag cag ctg aaa		408
Val Arg Arg Leu Arg Glu Val Val Leu Lys Pro Gly Gln Leu Lys		
80 85 90		
gca gtt ctt tgt gca gac cat gga gaa aaa ctg cag ctc ttc tgt cag		456
Ala Val Leu Cys Ala Asp His Gly Glu Lys Leu Gln Leu Phe Cys Gln		
95 100 105		
gag gat ggg aag gag aag ttt cag gag tct cta aag aag ctg aag aac		504
Glu Asp Gly Lys Glu Lys Phe Gln Glu Ser Leu Lys Lys Leu Lys Asn		
110 115 120 125		
gag gag cag gaa gct gag aag cta aca gct ttt atc aga gag aag aag		552
Glu Glu Gln Glu Ala Glu Lys Leu Thr Ala Phe Ile Arg Glu Lys Lys		
130 135 140		
aca tcc tgg aag gca agg gag act ttt tct gaa gat gtc ctg ggg cag		600
Thr Ser Trp Lys Ala Arg Glu Thr Phe Ser Glu Asp Val Leu Gly Gln		
145 150 155		
gaa tca tgg cag agt aca aat gca agg gaa aat gca ggg atc cca ggg		648
Glu Ser Trp Gln Ser Thr Asn Ala Arg Glu Asn Ala Gly Ile Pro Gly		
160 165 170		
ctg gag get gcc cac ttc tgg att gcc atc cct ttc tgt gcc atg tat		696
Leu Glu Ala Ala His Phe Trp Ile Ala Ile Pro Phe Cys Ala Met Tyr		
175 180 185		
ctt gta gca ctg gtt gga aat gct gcc ctc atc ctg gtc att gcc atg		744
Leu Val Ala Leu Val Gly Asn Ala Ala Leu Ile Leu Val Ile Ala Met		
190 195 200 205		
gac aat gct ctt cat gca cct atg tac ctc ctc tgc ctt ctc tca		792
Asp Asn Ala Leu His Ala Pro Met Tyr Leu Phe Leu Cys Leu Leu Ser		
210 215 220		



WO 01/75093


ctc aca gac ctg gct ctc agt tct acc act qtq ccc aag atg ctg gcc Leu Thr Asp Leu Ala Leu Ser Ser Thr Thr Val Pro Lys Met Leu Ala 225 230 235	840
att ttg tgg ctc cat gct ggt gag att tcc ttt ggt gga tgc ctg gcc Ile Leu Trp Leu His Ala Gly Glu Ile Ser Phe Gly Gly Cys Leu Ala 240 245 250	888
cag atg ttt tgt gtc cat tct atc tat gct ctg gag tcc tcg att cta Gln Met Phe Cys Val His Ser Ile Tyr Ala Leu Glu Ser Ser Ile Leu 255 260 265	936
ctt gcc atg gcc ttt gat agg tat gtg gct atc tgt aac cca tta agg Leu Ala Met Ala Phe Asp Arg Tyr Val Ala Ile Cys Asn Pro Leu Arg 270 275 280 285	984
tat aca acc att ctc aac cat gct gtc ata ggc aga att ggc ttt gtt Tyr Thr Ile Leu Asn His Ala Val Ile Gly Arg Ile Gly Phe Val 290 295 300	1032
ggg cta ttc cgt agt gtg gct att gtc tcc ccc ttc atc ttc ttg ctg Gly Leu Phe Arg Ser Val Ala Ile Val Ser Pro Phe Ile Phe Leu Leu 305 310 315	1080
agg cga ctc ccc tac tgt ggt cac cgt gtc atg aca cac aca tac tgt Arg Arg Leu Pro Tyr Cys Gly His Arg Val Met Thr His Thr Tyr Cys 320 325 330	1128
gag cat atg ggc atc gcc cga ctg gcc ttt ggc aac atc act gtc aat Glu His Met Gly Ile Ala Arg Leu Ala Cys Ala Asn Ile Thr Val Asn 335 340 345	1176
att gtc tat ggg cta act gtg gct ctg ctg gcc atg gga ctg gat tcc Ile Val Tyr Gly Leu Thr Val Ala Leu Leu Ala Met Gly Leu Asp Ser 350 355 360 365	1224
att ctc att gcc att tcc tat ggc ttt atc ctc cat gca gtc ttt cac Ile Leu Ile Ala Ile Ser Tyr Gly Phe Ile Leu His Ala Val Phe His 370 375 380	1272
ctt cca tct cat gat gcc cag cac aaa gct ctg agt acc tgt ggc tcc Leu Pro Ser His Asp Ala Gln His Lys Ala Leu Ser Thr Cys Gly Ser 385 390 395	1320
cac att ggc atc atc ctg gtt ttc tac atc cct gcc ttc ttc tcc ttc His Ile Gly Ile Ile Leu Val Phe Tyr Ile Pro Ala Phe Phe Ser Phe 400 405 410	1368
ctc acc cac cgc ttt ggt cac cac gaa gtc ccc aag cat gtg cac atc Leu Thr His Arg Phe Gly His His Glu Val Pro Lys His Val His Ile 415 420 425	1416
ttt ctg gct aat ctc tat gtg ctg gtg cct cct gta ctc aat cct att Phe Leu Ala Asn Leu Tyr Val Leu Val Pro Pro Val Leu Asn Pro Ile 430 435 440 445	1464
ctc tat gga gct aga acc aag gag att cgg agt cga ctt cta aaa ctg Leu Tyr Gly Ala Arg Thr Lys Glu Ile Arg Ser Arg Leu Leu Lys Leu 450 455 460	1512
ctt cac ctg ggg aag act tca ata tga Leu His Leu Gly Lys Thr Ser Ile 465	1539



Thr Arg Ala His Val Arg Arg Val Leu Gly Ala Val Trp Gly Leu Ala
 195 200 205
 Met Leu Cys Ser Leu Pro Asn Thr Ser Leu His Gly Ile Arg Gln Leu
 210 215 220
 His Val Pro Cys Arg Gly Pro Val Pro Asp Ser Ala Val Cys Met Leu
 225 230 235 240
 Val Pro Pro Arg Ala Leu Tyr Asn Met Val Val Gln Thr Thr Ala Leu
 245 250 255
 Leu Phe Phe Cys Leu Pro Met Ala Ile Met Ser Val Leu Tyr Leu Leu
 260 265 270
 Ile Gly Leu Arg Leu Arg Arg Glu Arg Leu Leu Met Gln Glu Ala
 275 280 285
 Lys Gly Arg Gly Ser Ala Ala Ala Arg Ser Arg Tyr Thr Cys Arg Leu
 290 295 300
 Gln Gln His Asp Arg Gly Arg Arg Gln Val Thr Lys Met Leu Phe Val
 305 310 315 320
 Leu Val Val Phe Gly Ile Cys Trp Ala Pro Phe His Ala Asp Arg
 325 330 335
 Val Met Trp Ser Val Val Ser Gln Trp Thr Asp Gly Leu His Leu Ala
 340 345 350
 Phe Gln His Val His Val Ile Ser Gly Ile Phe Phe Tyr Leu Gly Ser
 355 360 365
 Ala Ala Asn Pro Val Leu Tyr Ser Leu Met Ser Ser Arg Phe Arg Glu
 370 375 380
 Thr Phe Gln Glu Ala Leu Cys Leu Gly Ala Cys Cys His Arg Leu Arg
 385 390 395 400
 Pro Arg His Ser Ser His Ser Leu Ser Arg Met Thr Thr Gly Ser Thr
 405 410 415
 Leu Cys Asp Val Gly Ser Leu Gly Ser Trp Val His Pro Leu Ala Gly
 420 425 430
 Asn Asp Gly Pro Glu Ala Gln Gln Glu Thr Asp Pro Ser
 435 440 445

<210> 54
 <211> 469
 <212> PRT
 <213> Homo sapiens

<400> 54
 Met Thr Ser Pro Val Leu Val Asp Ile Arg Glu Glu Val Thr Cys Pro
 1 5 10 15
 Ile Cys Leu Glu Leu Leu Thr Glu Pro Leu Ser Ile Asp Cys Gly His
 20 25 30
 Ser Phe Cys Gln Ala Cys Ile Thr Pro Asn Gly Arg Glu Ser Val Ile
 35 40 45
 Gly Gln Glu Gly Glu Arg Ser Cys Pro Val Cys Gln Thr Ser Tyr Gln
 50 55 60
 Pro Gly Asn Leu Arg Pro Asn Arg His Leu Ala Asn Ile Val Arg Arg
 65 70 75 80
 Leu Arg Glu Val Val Leu Gly Pro Gly Lys Gln Leu Lys Ala Val Leu
 85 90 95
 Cys Ala Asp His Gly Glu Lys Leu Gln Leu Phe Cys Gln Glu Asp Gly
 100 105 110
 Lys Glu Lys Phe Gln Glu Ser Leu Lys Leu Lys Asn Glu Glu Gln
 115 120 125
 Glu Ala Glu Lys Leu Thr Ala Phe Ile Arg Glu Lys Lys Thr Ser Trp
 130 135 140
 Lys Ala Arg Glu Thr Phe Ser Glu Asp Val Leu Gly Gln Glu Ser Trp
 145 150 155 160
 Gln Ser Thr Asn Ala Arg Glu Asn Ala Gly Ile Pro Gly Leu Glu Ala
 165 170 175



Ala His Phe Trp Ile Ala Ile Pro Phe Cys Ala Met Tyr Leu Val Ala
 180 185 190
 Leu Val Gly Asn Ala Ala Leu Ile Leu Val Ile Ala Met Asp Asn Ala
 195 200 205
 Leu His Ala Pro Met Tyr Leu Phe Leu Cys Leu Leu Ser Leu Thr Asp
 210 215 220
 Leu Ala Leu Ser Ser Thr Thr Val Pro Lys Met Leu Ala Ile Leu Trp
 225 230 235 240
 Leu His Ala Gly Glu Ile Ser Phe Gly Gly Cys Leu Ala Gln Met Phe
 245 250 255
 Cys Val His Ser Ile Tyr Ala Leu Glu Ser Ser Ile Leu Leu Ala Met
 260 265 270
 Ala Phe Asp Arg Tyr Val Ala Ile Cys Asn Pro Leu Arg Tyr Thr Thr
 275 280 285
 Ile Leu Asn His Ala Val Ile Gly Arg Ile Gly Phe Val Gly Leu Phe
 290 295 300
 Arg Ser Val Ala Ile Val Ser Pro Phe Ile Phe Leu Leu Arg Arg Leu
 305 310 315 320
 Pro Tyr Cys Gly His Arg Val Met Thr His Thr Tyr Cys Glu His Met
 325 330 335
 Gly Ile Ala Arg Leu Ala Cys Ala Asn Ile Thr Val Asn Ile Val Tyr
 340 345 350
 Gly Leu Thr Val Ala Leu Leu Ala Met Gly Leu Asp Ser Ile Leu Ile
 355 360 365
 Ala Ile Ser Tyr Gly Phe Ile Leu His Ala Val Phe His Leu Pro Ser
 370 375 380
 His Asp Ala Gln His Lys Ala Leu Ser Thr Cys Gly Ser His Ile Gly
 385 390 395 400
 Ile Ile Leu Val Phe Tyr Ile Pro Ala Phe Phe Ser Phe Leu Thr His
 405 410 415
 Arg Phe Gly His His Glu Val Pro Lys His Val His Ile Phe Leu Ala
 420 425 430
 Asn Leu Tyr Val Leu Val Pro Pro Val Leu Asn Pro Ile Leu Tyr Gly
 435 440 445
 Ala Arg Thr Lys Glu Ile Arg Ser Arg Leu Leu Lys Leu Leu His Leu
 450 455 460
 Gly Lys Thr Ser Ile
 465

<210> 55
 <211> 195
 <212> PRT
 <213> Homo sapiens

<400> 55
 Met Gly Arg Ala Arg Asp Ala Ile Leu Asp Ala Leu Glu Asn Leu Thr
 1 5 10 15
 Ala Glu Glu Leu Lys Lys Phe Lys Leu Lys Leu Leu Ser Val Pro Leu
 20 25 30
 Arg Glu Gly Tyr Gly Arg Ile Pro Arg Gly Ala Leu Leu Ser Met Asp
 35 40 45
 Ala Leu Asp Leu Thr Asp Lys Leu Val Ser Phe Tyr Leu Glu Thr Tyr
 50 55 60
 Gly Ala Glu Leu Thr Ala Asn Val Leu Arg Asp Met Gly Leu Gln Glu
 65 70 75 80
 Met Ala Gly Gln Leu Gln Ala Ala Thr His Gln Gly Ser Gly Ala Ala
 85 90 95
 Pro Ala Gly Ile Gln Ala Pro Pro Gln Ser Ala Ala Lys Pro Gly Leu
 100 105 110
 His Phe Ile Asp Gln His Arg Ala Ala Leu Ile Ala Arg Val Thr Asn
 115 120 125

